248 related articles for article (PubMed ID: 23307576)
1. Involvement of PDGF in fibrosis and scleroderma: recent insights from animal models and potential therapeutic opportunities.
Iwayama T; Olson LE
Curr Rheumatol Rep; 2013 Feb; 15(2):304. PubMed ID: 23307576
[TBL] [Abstract][Full Text] [Related]
2. SSc in 2011: From mechanisms to medicines.
Mouthon L
Nat Rev Rheumatol; 2012 Jan; 8(2):72-4. PubMed ID: 22231235
[TBL] [Abstract][Full Text] [Related]
3. Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate.
Pannu J; Asano Y; Nakerakanti S; Smith E; Jablonska S; Blaszczyk M; ten Dijke P; Trojanowska M
Arthritis Rheum; 2008 Aug; 58(8):2528-37. PubMed ID: 18668566
[TBL] [Abstract][Full Text] [Related]
4. Future treatments in systemic sclerosis.
Asano Y
J Dermatol; 2010 Jan; 37(1):54-70. PubMed ID: 20175840
[TBL] [Abstract][Full Text] [Related]
5. Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?
Beyer C; Distler JH; Distler O
Swiss Med Wkly; 2010; 140():w13050. PubMed ID: 20419513
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
[TBL] [Abstract][Full Text] [Related]
7. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis.
Akhmetshina A; Venalis P; Dees C; Busch N; Zwerina J; Schett G; Distler O; Distler JH
Arthritis Rheum; 2009 Jan; 60(1):219-24. PubMed ID: 19116940
[TBL] [Abstract][Full Text] [Related]
8. Imatinib and the treatment of fibrosis: recent trials and tribulations.
Gordon J; Spiera R
Curr Rheumatol Rep; 2011 Feb; 13(1):51-8. PubMed ID: 21086081
[TBL] [Abstract][Full Text] [Related]
9. [A new therapeutic avenue for severe systemic sclerosis: imatinib mesylate].
Taïeb A; Constans J; Mahon FX
Rev Med Interne; 2008 Mar; 29(3):173-5. PubMed ID: 17597261
[No Abstract] [Full Text] [Related]
10. Is imatinib mesylate a promising drug in systemic sclerosis?
van Daele PL; Dik WA; Thio HB; van Hal PT; van Laar JA; Hooijkaas H; van Hagen PM
Arthritis Rheum; 2008 Aug; 58(8):2549-52. PubMed ID: 18668570
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies.
Distler JH; Distler O
Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i48-51. PubMed ID: 19995744
[TBL] [Abstract][Full Text] [Related]
12. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting.
Pietras K; Pahler J; Bergers G; Hanahan D
PLoS Med; 2008 Jan; 5(1):e19. PubMed ID: 18232728
[TBL] [Abstract][Full Text] [Related]
13. Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors.
Maurer B; Distler A; Dees C; Khan K; Denton CP; Abraham D; Gay RE; Michel BA; Gay S; Hw Distler J; Distler O
Ann Rheum Dis; 2013 Dec; 72(12):2039-46. PubMed ID: 24013728
[TBL] [Abstract][Full Text] [Related]
14. The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis.
Asano Y; Bujor AM; Trojanowska M
J Dermatol Sci; 2010 Sep; 59(3):153-62. PubMed ID: 20663647
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials.
Iwamoto N; Distler JH; Distler O
Curr Rheumatol Rep; 2011 Feb; 13(1):21-7. PubMed ID: 21042889
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial.
Prey S; Ezzedine K; Doussau A; Grandoulier AS; Barcat D; Chatelus E; Diot E; Durant C; Hachulla E; de Korwin-Krokowski JD; Kostrzewa E; Quemeneur T; Paul C; Schaeverbeke T; Seneschal J; Solanilla A; Sparsa A; Bouchet S; Lepreux S; Mahon FX; Chene G; Taïeb A
Br J Dermatol; 2012 Nov; 167(5):1138-44. PubMed ID: 23039171
[TBL] [Abstract][Full Text] [Related]
17. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease.
Khanna D; Saggar R; Mayes MD; Abtin F; Clements PJ; Maranian P; Assassi S; Saggar R; Singh RR; Furst DE
Arthritis Rheum; 2011 Nov; 63(11):3540-6. PubMed ID: 21769849
[TBL] [Abstract][Full Text] [Related]
18. Targeting PDGF signaling in carcinoma-associated fibroblasts controls cervical cancer in mouse model.
Jain RK; Lahdenranta J; Fukumura D
PLoS Med; 2008 Jan; 5(1):e24. PubMed ID: 18232729
[TBL] [Abstract][Full Text] [Related]
19. Notch Signaling Activity Determines Uptake and Biological Effect of Imatinib in Systemic Sclerosis Dermal Fibroblasts.
Harrach S; Barz V; Pap T; Pavenstädt H; Schlatter E; Edemir B; Distler J; Ciarimboli G; Bertrand J
J Invest Dermatol; 2019 Feb; 139(2):439-447. PubMed ID: 30273596
[TBL] [Abstract][Full Text] [Related]
20. Blockade of PDGF Receptors by Crenolanib Has Therapeutic Effect in Patient Fibroblasts and in Preclinical Models of Systemic Sclerosis.
Makino K; Makino T; Stawski L; Mantero JC; Lafyatis R; Simms R; Trojanowska M
J Invest Dermatol; 2017 Aug; 137(8):1671-1681. PubMed ID: 28433542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]